Charles Peeples, MD
Internal Medicine · Oakhurst, NJNPI 1477558518
Payments from drug & device makers
Across 472 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$731
- Novo Nordisk$617
- Johnson & Johnson$524
- AbbVie$522
- Pfizer$507
- plus $2K from 28 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$6,705100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 128 | $2,062 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $731 |
| Novo Nordisk | 43 | $617 |
| Johnson & Johnson | 42 | $524 |
| AbbVie(2 entities) | 41 | $522 |
| Pfizer | 44 | $507 |
| Merck | 19 | $247 |
| Boehringer Ingelheim | 17 | $244 |
| Amarin Pharma, Inc. | 13 | $186 |
| Lilly USA, LLC | 10 | $148 |
| Eisai Inc. | 7 | $97 |
| GSK | 7 | $96 |
| Amgen(2 entities) | 7 | $95 |
| Indivior Inc. | 6 | $74 |
| Scilex Pharmaceuticals Inc. | 4 | $57 |
| Exact Sciences | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 4 | $55 |
| Astellas Pharma US Inc | 4 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Alkermes, Inc. | 2 | $35 |
| Abbott | 2 | $32 |
| Optos, Inc. | 1 | $32 |
| Orexo US, Inc. | 2 | $30 |
| Bayer | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Vivus LLC | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
How this compares
$6,720 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 55 | $106,593 |
| FarxigaDapagliflozin Propanediol | 39 | $44,836 |
| OzempicSemaglutide | 28 | $41,014 |
| JardianceEmpagliflozin | 24 | $38,817 |
| TradjentaLinagliptin | 22 | $30,360 |
| Nurtec OdtRimegepant Sulfate | 14 | $23,209 |
| JanuviaSitagliptin Phosphate | 16 | $21,077 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $19,287 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 116 | $18,156 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,204 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,262 |
| BelsomraSuvorexant | 28 | $11,944 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,782 |
| Xtampza ErOxycodone Myristate | 11 | $7,683 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $6,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $244 | $69,17746 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $2,062 | $65,05478 claims |
| MerckJanuvia, Janumet, Belsomra | $247 | $52,30859 claims |
| Novo NordiskOzempic | $617 | $41,01428 claims |
| PfizerNurtec Odt | $507 | $23,20914 claims |
| GSKTrelegy Ellipta | $96 | $15,20415 claims |
| Indivior Inc.Suboxone | $74 | $6,88912 claims |
| AbbVieSynthroid | $522 | $1,71725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Oakhurst
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.